secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001437402-25-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx Q3 2025: product revenue $105.5M, IBSRELA +92% YoY, guidance raised
---------------------------------------------------------------------------

- Total Q3 product revenue $105.5M (+15% YoY); net loss $1.0M ($0.00 per share).
- IBSRELA revenue $78.2M (+92% YoY, +20% QoQ); 2025 guidance raised to $270-275M.
- XPHOZAH revenue $27.4M (+9% QoQ); YoY decline due to loss of Part D coverage.
- Cash $242.7M; new NHE3 inhibitor RDX10531 with IND submission targeted for 2026.
- Appointed Sue Hohenleitner as CFO effective Nov 4, plus new CMO and CTO in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000143740225000016/0001437402-25-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000143740225000016/ardx-20251030.htm
  HTML page:      https://secwatch.observer/filing/0001437402-25-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer